Clinical Study

Uccc-Gyn-20-01- Phase I Study Of Adjuvant Hypofractionated Whole Pelvis Radiation Therapy In Endometrial Cancer.

Posted Date: May 20, 2021

  • Investigator: Teresa Meier
  • Specialties: Cancer, Gynecologic Oncology, Oncology
  • Type of Study: Drug

The purpose of this study is to evaluate the safety of adjuvant hypofractionated whole pelvis radiation therapy (WPRT) in endometrial cancer. The primary objective of the study is to determine the maximum tolerated dose per fraction (MTDF), defined by acceptable acute clinician-reported GI and GU toxicity and patient-reported GI toxicity, of WPRT from among the two study dose levels


Must Have Histologically Confirmed Stage I, Ii, Or Iii Endometrial Cancer That Requires Pelvic Radiation, Ecog 0-2, Must Have Undergone Total Hysterectomy And Bilateral Salpingo-Oophorectomy With Or Without Pelvic And/Or Para-Aortic Lymph Node Dissection/Sampling Or Sentinel Lymph Node (Sln) Dissection, No Inflammatory Bowel Disease, No Current, Active Disease Involving Periaortic Node(S), No Gross Residual Disease Following Surgical Resection, No Prior Pelvic Radiotherapy, No Uncontrolled Intercurrent Illness


Endometrial Cancer, Gynecology

For More Information:

Uc Cancer Center